Last reviewed · How we verify
Phase 2 Trial of First-Line Therapy With Satraplatin and Paclitaxel in Patients With Unresectable Stage III or IV Non-small Cell Lung Cancer (NSCLC)
The purpose of this trial is to study the combination regimen of satraplatin and paclitaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC).
Details
| Lead sponsor | Agennix |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 40 |
| Start date | 2005-12 |
| Completion | 2009-09 |
Conditions
- Non-small Cell Lung Cancer
Interventions
- Satraplatin in combination with Paclitaxel
Primary outcomes
- To examine overall response rates in patients with advanced NSCLC treated with a first-line regimen of satraplatin and paclitaxel — 3 months
Countries
United States